Skip To Main Content
Ben Hirschler on Muck Rack

Ben Hirschler

London
As seen in: MSN, UOL, Business Insider, Daily Mail, HuffPost, Reuters, Terra, The Economic Times, The Independent (UK), The Times of India and
Former #Reuters global pharmaceuticals correspondent in London. Now freelance writer and consultant.

Get in touch with Ben

Contact Ben, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

China Takes the Lead on Biotech

|
By Ben Hirschler, Francesca Scassellati Sforzolini, Yi Zhou
| Brunswick Review Verified
These days, the hottest innovations in biotechnology are just as likely to come from Shanghai and Beijing as Boston or San Francisco. Once regarded as merely a producer of cheap generic medicines, China has made huge strides in life sciences in recent years, creating novel medicines that have grabbed the attention of the world’s biggest pharmaceutical companies. Around one third of the money spent on drug licensing deals in 2024 was ploughed into products originating in Chinese laboratories.
Open in Who Shared Issue with article?

A Legal View on AI in Healthcare: Balancing Opportunity and Risk

|
By Agnes Brandt, Ben Hirschler
| Brunswick Group
An interview with Linklaters’ Georgina Kon, a Partner specializing in complex domestic and international IT, sourcing and information governance matters. As artificial intelligence (AI) rapidly evolves, regulators and policymakers are racing to catch up, seeking to impose the right safeguards without stifling innovation. While every sector is trying to understand the promise and pitfalls of AI, the stakes are especially high in healthcare.
Open in Who Shared Issue with article?

The EU’s New Pharma Rules: A Once-in-a-Generation Opportunity or a Missed Chance?

|
By Ben Hirschler, Francesca Scassellati Sforzolini
| Brunswick Group
Europe is updating its rules for how it regulates the pharmaceutical and life sciences industry – with far-reaching implications for its life sciences ecosystem. With the fine print to be negotiated over the coming months, companies still have time to make the case for innovation and ensure Europe doesn’t miss out on a once-in-a-generation opportunity. Are you ready for Europe’s new pharma rules? In the run-up to elections in June, Europe is getting ready to finalise new rules for pharmaceuticals.
Open in Who Shared Issue with article?
See all 2,097 licensed articles (4,328 Total)